# Nepafenac 0.3% Two Study

> **NCT01318499** · PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 1342 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Nepafenac Ophthalmic Suspension, 0.3%
- **DRUG:** Nepafenac Ophthalmic Suspension, 0.1%
- **OTHER:** Nepafenac Vehicle 0.3%

## Key facts

- **NCT ID:** NCT01318499
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 1342 (ACTUAL)
- **Last updated:** 2012-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318499, "Nepafenac 0.3% Two Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01318499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*